{"id":46746,"date":"2022-07-29T18:01:41","date_gmt":"2022-07-29T16:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/"},"modified":"2022-07-29T18:01:41","modified_gmt":"2022-07-29T16:01:41","slug":"cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/","title":{"rendered":"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382809\/cathepsin-k-inhibitor-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6gchnz&amp;utm_campaign=1732687+-+Cathepsin+K+Inhibitor+Pipeline+Research+Report+2022+Featuring+Medivir+AB%2C+Celera+Group%2C+Merck+%26+Co%2C+Mateon+Therapeutics%2C+%26+Amura&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/21\/logo.jpg\"><\/a><\/p>\n<p>\n&#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin K Inhibitor development.\n<\/p>\n<p>\nThe report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.\n<\/p>\n<p>\n<strong>Descriptive coverage of pipeline development activities for Cathepsin K Inhibitor<\/strong>\n<\/p>\n<p>\nPipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&amp;D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.\n<\/p>\n<p>\n<strong>Pipeline Therapeutics assessment of products for Cathepsin K Inhibitor<\/strong>\n<\/p>\n<p>\nThe report assesses the active Cathepsin K Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.\n<\/p>\n<p>\n<strong>Scope of the Report<\/strong>\n<\/p>\n<ul>\n<li>\nProvides a snapshot of the therapeutics pipeline activity for Cathepsin K Inhibitor\n<\/li>\n<li>\nFeatures the Cathepsin K Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages\n<\/li>\n<li>\nOffers detailed therapeutic product profiles of Cathepsin K Inhibitor with key coverage of developmental activities including licensing &amp; collaboration deals, patent details, designations, technologies, indications and chemical information\n<\/li>\n<li>\nTherapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration\n<\/li>\n<li>\nCoverage of dormant and discontinued pipeline projects across Cathepsin K Inhibitor\n<\/li>\n<\/ul>\n<p>\n<strong>Reasons to Buy<\/strong>\n<\/p>\n<ul>\n<li>\nEstablish a comprehensive understanding of the current pipeline scenario across Cathepsin K Inhibitor to formulate effective R&amp;D strategies\n<\/li>\n<li>\nAssess challenges and opportunities that influence Cathepsin K Inhibitor research &amp; development (R&amp;D)\n<\/li>\n<li>\nGather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage\n<\/li>\n<li>\nIdentify and understand the sought after therapy areas and indications for Cathepsin K Inhibitor\n<\/li>\n<li>\nIdentify the product attributes and use it for target finding, drug repurposing, and precision medicine\n<\/li>\n<li>\nDevise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Cathepsin K Inhibitor to enhance and expand business potential and scope\n<\/li>\n<li>\nPlan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress\n<\/li>\n<li>\nThe extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Report Introduction<\/strong>\n<\/p>\n<p>\n<strong>2. Cathepsin K Inhibitor &#8211; Overview<\/strong>\n<\/p>\n<p>\n<strong>3. Pipeline Therapeutics<\/strong>\n<\/p>\n<ul>\n<li>\nAn Overview of Pipeline Products for Cathepsin K Inhibitor\n<\/li>\n<\/ul>\n<p>\n<strong>4. Comparative Analysis<\/strong>\n<\/p>\n<p>\n<strong>5. Cathepsin K Inhibitor Pipeline Products in Clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>6. Cathepsin K Inhibitor Pipeline Products in Non-clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>7. Therapeutic Assessment: Active Products<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Assessment by Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Stage and Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Molecule Type\n<\/li>\n<li>\nPipeline Assessment by Stage and Molecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>8. Inactive Pipeline Products<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<li>\nReason for dormancy\/discontinuation\n<\/li>\n<\/ul>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nMedivir AB\n<\/li>\n<li>\nCelera Group\n<\/li>\n<li>\nMerck &amp; Co\n<\/li>\n<li>\nMateon Therapeutics\n<\/li>\n<li>\nAmura\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382809\/cathepsin-k-inhibitor-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6gchnz&amp;utm_campaign=1732687+-+Cathepsin+K+Inhibitor+Pipeline+Research+Report+2022+Featuring+Medivir+AB%2C+Celera+Group%2C+Merck+%26+Co%2C+Mateon+Therapeutics%2C+%26+Amura&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/alqsnd<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x70;&#114;&#x65;&#115;&#x73;&#64;&#x72;&#101;&#x73;&#101;&#x61;&#114;&#x63;&#104;&#x61;&#110;&#x64;&#109;&#x61;&#114;&#x6b;&#101;&#x74;&#115;&#x2e;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#101;&#x73;s&#64;&#x72;&#101;&#x73;e&#x61;r&#99;&#x68;&#97;&#x6e;d&#x6d;&#x61;&#114;&#x6b;e&#x74;s&#46;&#x63;&#111;&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin K Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46746","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin K Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-29T16:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-07-29T16:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/\"},\"wordCount\":599,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005384\\\/en\\\/1529447\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/\",\"name\":\"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005384\\\/en\\\/1529447\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-07-29T16:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005384\\\/en\\\/1529447\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005384\\\/en\\\/1529447\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Cathepsin K Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin K Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-29T16:01:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura &#8211; ResearchAndMarkets.com","datePublished":"2022-07-29T16:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/"},"wordCount":599,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/","name":"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/21\/logo.jpg","datePublished":"2022-07-29T16:01:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220729005384\/en\/1529447\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cathepsin-k-inhibitor-pipeline-research-report-2022-featuring-medivir-ab-celera-group-merck-co-mateon-therapeutics-amura-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cathepsin K Inhibitor Pipeline Research Report 2022 Featuring Medivir AB, Celera Group, Merck &amp; Co, Mateon Therapeutics, &amp; Amura &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46746"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46746\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}